Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Novo Nordisk has ousted chief executive Lars Fruergaard Jørgensen as the maker of pioneering obesity drug Ozempic battles a slump in profit growth, declining market share and a plunging stock price.

Forget the needle.

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant ...

If you make a purchase via links on this page we will earn commission - learn more Ozempic and Wegovy are household names that have revolutionized the weight loss industry — a market already ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Similar to other Ozempic-like drugs, the pill is part of the GLP-1 receptor family, which help regulate blood sugar and appetite. There is a GLP-1 pill on the market now called Rybelsus, however it ...

Brigham Buhler, a MAHA influencer and biotech entrepreneur, has Robert F. Kennedy’s ear. But will RFK listen to his call to ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...